Gilead Sciences (NASDAQ: GILD) and Arcellx (NASDAQ: ACLX) were in sharp focus today after Gilead agreed to acquire Arcellx in a transaction valued at an implied equity value of $7.8 billion. The announcement sparked an explosive move in Arcellx shares in pre-market trading, while Gilead’s stock showed modest early weakness as investors weighed the price tag and the longer-term payoff tied to the deal’s lead asset.
In early trading indications, ACLX surged by roughly 80%, snapping toward the takeover price and putting the stock on track for a potential all-time high if those levels hold through the open. By contrast, GILD was indicated slightly lower in pre-market action, a common reaction when a large-cap buyer announces a multi-billion-dollar acquisition funded primarily by cash.
Deal terms: $115 cash plus a $5 CVR
Under the definitive agreement, Gilead will pay $115 per share in cash at closing and issue one non-transferable contingent value right (CVR) worth $5 per share. The CVR is tied to commercial performance milestones linked to Arcellx’s lead program, creating a pathway for shareholders to receive additional value if sales targets are met after launch.
The offer represents a substantial premium to Arcellx’s recent trading levels. The deal structure is designed to provide immediate certainty through cash consideration, while also retaining upside via the CVR if the core therapy becomes a major revenue driver over time.
Why ACLX stock surged nearly 80% today
The rally in Arcellx shares is primarily a classic merger-arbitrage repricing. Once the market digests a definitive agreement with clearly stated per-share consideration, the target’s stock tends to gap sharply toward the deal value, with the remaining spread reflecting closing risk and the time value of money.
Arcellx was trading far below the stated $115 cash component before the announcement, so the deal instantly reset expectations for what the company is worth to a strategic buyer. The additional $5 CVR added another layer of potential upside, amplifying enthusiasm among investors who believe the lead therapy could scale to blockbuster sales.
The strategic centerpiece: anito-cel in multiple myeloma
The acquisition builds on the companies’ earlier collaboration around anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for patients with relapsed or refractory multiple myeloma. In studies to date, anito-cel has shown deep responses with a safety profile that management describes as predictable and manageable, a key point in a space where toxicity and manufacturing timelines can heavily influence adoption.
The therapy is approaching a critical regulatory window, with an FDA review timeline already in motion. That matters because the most valuable period for any potential first launch is the early commercial ramp, when clinicians establish prescribing habits and payers lock in coverage frameworks.
Why Gilead wants full control
For Gilead, the logic of buying Arcellx outright is centered on consolidation and speed. Full ownership can streamline decision-making, reduce complexity around profit-sharing, and align development priorities across clinical, manufacturing, and commercial teams. The goal is to accelerate broader commercialization while removing long-term economic leakage from milestones, royalties, or shared profit splits that often come with partnership structures.
Beyond anito-cel, Arcellx brings a technology platform designed to generate proprietary binders with improved specificity and binding affinity. That platform value is harder to model in the near term, but it can matter materially over time if it becomes a repeatable engine for next-generation cell therapies or related immunotherapy approaches.
How GILD stock is trading and what investors are watching
Gilead’s early dip reflects a familiar investor checklist: acquisition pricing, integration risk, and the timeline to meaningful earnings contribution. Management expects the transaction to become accretive to earnings per share starting in 2028 and beyond, which naturally places the payoff several years out, even as the upfront cash outlay is immediate.
That said, Gilead’s broader operating backdrop remains important. The company continues to lean on established franchises while pushing deeper into oncology, and investors will be sensitive to whether capital allocation supports sustainable growth without compromising near-term financial flexibility.
Key timeline: closing and the regulatory runway
The deal is expected to close in Q2 2026, subject to customary closing conditions and regulatory approvals. Between now and close, markets will focus on the tender process, the pace of approvals, and any updates around the therapy’s clinical and regulatory package.
On the product side, the next major inflection is regulatory action on anito-cel later this year, followed by launch execution and manufacturing scale, which are often decisive for cell therapy outcomes in real-world adoption.
Bottom line for today’s price action
Arcellx’s surge is the market rapidly converging on the takeover value, while Gilead’s mild pullback reflects investors balancing the strategic upside against near-term acquisition costs. The big determinant from here will be confidence in the therapy’s commercial trajectory and the buyer’s ability to accelerate development and access without friction.
For a quick read on the transaction headline and market reaction, see Reuters coverage.
